EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, VRTX: Vertex Pharmaceutic

05 Mar 26 18:32
LAST:

460.8

CHANGE:
 17.07		OPEN:
476.6		HIGH:
480.0		ASK:
170.0		VOLUME:
1.11M
CHG(%):
3.57		PREV:
477.9		LOW:
457.0		BID:
149.8		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
05 Mar 26476.6480.0457.0460.81.11M
04 Mar 26475.3480.7470.4477.9996.3K
03 Mar 26479.0484.1471.6474.31.06M
02 Mar 26496.6498.0484.4486.01.03M
27 Feb 26480.3497.8479.8496.81.78M
26 Feb 26483.4483.6474.6480.11.31M
25 Feb 26486.4492.3481.7483.1820.9K
24 Feb 26479.2491.2479.0487.41.33M
23 Feb 26475.1487.6475.1481.01.24M
20 Feb 26466.9479.1465.0476.91.01M

PROFILE

Name:Vertex Pharmaceutic
About:Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Sector:Healthcare
Industry:Biotechnology
Address:50 Northern Avenue, Boston, MA, United States, 02210
Website:https://www.vrtx.com
CUSIP:92532F100
CIK:0000875320
ISIN:US92532F1003
FIGI:BBG000C1S2X2
LEI:54930015RAQRRZ5ZGJ91

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:34.02 
Forward P/E:23.97 
PEG Ratio:-0.24 
Price to Sales:9.56 
Price to Book:7.10 
Profit Margin:0.32 
Operating Margin:0.39 
Return on Assets:0.13 
Return on Equity:0.23 
EPS Ratio:14.23 
Revenue:11.419B 
EBITDA:485.8M 
Shares:253.72M 
Market Cap:116.919B 

TECHNICAL INDICATORS

MA5:479.174.0%
MA10:480.444.3%
MA20:475.503.2%
MA50:467.521.5%
MA100:448.842.7%
MA200:437.085.4%
RSI14:48.43
WPR14:-100.00 
MTM14:-30.65
ROC14:-0.06 
ATR:15.56 
Week High:498.038.1%
Week Low:457.000.8%
Month High:503.889.3%
Month Low:454.405.4%
Year High:519.6812.8%
Year Low:362.5027.1%
Volatility:19.56 

RECENT SPLITS

Date Ratio
24 Aug 20002-1